Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from ContraFect

CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility…

Bautz: By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Benzinga · Jul 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022

Upgrades

Benzinga · Jul 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

Upgrades

Benzinga · Jun 8, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

CFRX: Results from Interim Futility Analysis in July 2022…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Benzinga · May 26, 2022

ContraFect: Q1 Earnings Insights

ContraFect (NASDAQ:CFRX) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga · May 16, 2022

Recap: ContraFect Q4 Earnings

ContraFect (NASDAQ:CFRX) reported its Q4 earnings results on Thursday, March 24, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings

Benzinga · Mar 24, 2022

Coverage From

Benzinga

People

David Bautz

41 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Antibiotics

1,205 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.